[artículo] 
inJournal of Clinical Psychopharmacology > Año 2011 - Vol. 31 - No. 2 (Abril) . - pp. 154-159

Título :	Metabolic effects of olanzapine in patients with newly diagnosed psychosis
Tipo de documento:	texto impreso
Autores:	Emilio Fernández Egea, Autor ; Brian J. Miller, Autor ; Clemente Garcia Rizo, Autor
Fecha de publicación:	2022
Artículo en la página:	pp. 154-159
Idioma :	Inglés (eng) Idioma original : Inglés (eng)
Palabras clave:	Olanzapina, Psicosis, Diabetes, Antecedentes familiares
Resumen:	Antipsychotic medications are associated with an increased risk of diabetes. Previous studies have also found an increased risk of type 2 diabetes mellitus in the relatives of schizophrenia probands. The aim of this study was to explore the metabolic adverse effects of olanzapine in a cohort of patients with newly diagnosed psychosis and minimal or no exposure to antipsychotics.
Link:	./index.php?lvl=notice_display&id=29383

[artículo] Metabolic effects of olanzapine in patients with newly diagnosed psychosis [texto impreso] / Emilio Fernández Egea, Autor ; Brian J. Miller, Autor ; Clemente Garcia Rizo, Autor . - 2022 . - pp. 154-159.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in Journal of Clinical Psychopharmacology > Año 2011 - Vol. 31 - No. 2 (Abril) . - pp. 154-159

Palabras clave:	Olanzapina, Psicosis, Diabetes, Antecedentes familiares
Resumen:	Antipsychotic medications are associated with an increased risk of diabetes. Previous studies have also found an increased risk of type 2 diabetes mellitus in the relatives of schizophrenia probands. The aim of this study was to explore the metabolic adverse effects of olanzapine in a cohort of patients with newly diagnosed psychosis and minimal or no exposure to antipsychotics.
Link:	./index.php?lvl=notice_display&id=29383